Actively Recruiting

Age: 18Years +
All Genders
ID04528511

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction: the BENEFIT-AMI Multicenter Prospective Registry

Led by Shanghai 10th People's Hospital · Updated on 2026-03-19

774

Participants Needed

5

Research Sites

26 weeks

Total Duration

On this page

Sponsors

S

Shanghai 10th People's Hospital

Lead Sponsor

S

Shanghai Tong Ren Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the importance of the burden of new-onset atrial fibrillation (NOAF) in patients who develop this condition during acute myocardial infarction (AMI) hospitalization. This study aims to confirm earlier findings that a higher NOAF burden leads to worse outcomes and to understand factors that contribute to increasing NOAF burden after a heart attack. The study also seeks to create a prediction model to help assess risk and to explore how NOAF burden can guide blood-thinning treatment decisions in these patients. Patients admitted for AMI who develop NOAF during hospitalization will be included. Participants will have continuous electronic monitoring (CEM) for at least 5 days to measure NOAF burden, calculated as the total duration of atrial fibrillation divided by the total monitoring time. Patients will be divided into low or high NOAF burden groups based on a previously established threshold of 10.87%. This multicenter registry involves data collection from multiple hospitals and includes demographic information, heart health factors, lab tests, and imaging results to fully characterize participants. After discharge, all patients who survive will be followed for at least 2 years to record cardiovascular outcomes such as death, heart failure hospitalizations, recurrent heart attacks, strokes, and major bleeding events. The primary outcome is all-cause death within one year. The study uses continuous heart rhythm monitoring during hospitalization and gathers detailed clinical information to understand the impact of NOAF burden and its role in guiding treatment. Participation involves data collection during hospital stay and long-term follow-up visits to assess health outcomes.

CONDITIONS

Brief Title

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients (>18 years old)
  • Patients with acute myocardial infarction (including STEMI and NSTEMI) who developed new-onset atrial fibrillation during the hospital stay
  • Patients must have received continuous electronic monitoring for at least 5 days during hospitalization
  • Patients must provide informed consent
Not Eligible

You will not qualify if you...

  • Patients with a history of atrial fibrillation before the current myocardial infarction
  • Patients with rheumatic valvular disease
  • Patients with sick sinus syndrome
  • Patients undergoing emergency coronary artery bypass surgery
  • Patients with malignant tumors expected to live less than 1 year
  • Patients who refuse continuous electronic monitoring or whose heart rhythm data cannot be collected
  • Patients who refuse or have contraindications for percutaneous coronary intervention (PCI)
  • Patients who died during the hospital stay

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

During hospitalization

Implementation

Duration - At least 5 days

Participants receive continuous electronic monitoring for at least 5 days during hospitalization to evaluate new-onset atrial fibrillation burden.

Continuous monitoring during hospital stay

Long-term Monitoring

Duration - At least 2 years

Participants discharged alive are followed for at least 2 years to record cardiovascular outcomes such as death, heart failure hospitalization, recurrent myocardial infarction, ischemic stroke, and major bleeding.

Follow-up visits during the 2-year period

Trial Site Locations

Total: 5 locations

1

Kaifeng Central Hospital

Kaifeng, Henan, China

Actively Recruiting

2

Luoyang Central Hospital

Luoyang, Henan, China

Actively Recruiting

3

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Actively Recruiting

4

Department of Cardiology, Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China, 200072

Actively Recruiting

5

Shanghai Seventh People's Hospital

Shanghai, Shanghai Municipality, China

Actively Recruiting

Loading map...

Research Team

J

Jiachen Luo, M.D., Ph.D.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Danish Study to Assess the Efficacy of Implantable Cardiov...

Coronary Artery Disease

Actively Recruiting

1 location

A Multicentre Observational Study to Assess Long-term Outcom...

Acute Myocardial Infarction

Actively Recruiting

10 locations

Abbott Vascular Medical Device Registry

Acute Myocardial Infarction

Actively Recruiting

37 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here